Christopher Mutz
Corporate Officer/Principal at ANI PHARMACEUTICALS, INC.
Net worth: 5 M $ as of 30/04/2024
Profile
Christopher K.
Mutz is currently the Senior Vice President & Head-Rare Diseases at ANI Pharmaceuticals, Inc. Previously, he worked as the National Sales Director-US Metabolic Business Unit at Alexion Pharmaceuticals, Inc. He completed his undergraduate degree at the University of Virginia and holds an MBA from the Johnson Graduate School of Management.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 21/05/2024 | 83,277 ( 0.40% ) | 5 M $ | 30/04/2024 |
Christopher Mutz active positions
| Companies | Position | Start |
|---|---|---|
| ANI PHARMACEUTICALS, INC. | Corporate Officer/Principal | 17/02/2021 |
Former positions of Christopher Mutz
| Companies | Position | End |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Training of Christopher Mutz
| University of Virginia | Undergraduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ANI PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Christopher Mutz
